Search Result

Results for "

PRB

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (4) c-Myc (2) CDK (12) ERK (2) FLT3 (2) JAK (2) Mitochondrial Metabolism (1) Molecular Glues (2) PI3K (3) Progesterone Receptor (2) PROTACs (2) RIO Kinase (1) Small Interfering RNA (siRNA) (7) STAT (2) Thrombopoietin Receptor (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (2) Endocrinology (3) Inflammation/Immunology (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (5) siRNAs (7)

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158106

AZD8421 1 Publications Verification	CDK	Cancer
AZD8421 is a selective CDK2 inhibitor (IC₅₀ = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer .

HY-129180

XY028-133	PROTACs CDK	Cancer
XY028-133 (example 14) is a PROTAC-based CDK4/6 degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK .

HY-162318

MYC degrader 1 1 Publications Verification	Molecular Glues c-Myc	Cancer
MYC degrader 1 (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .

HY-112158

NSC139021 1 Publications Verification ERGi-USU	RIO Kinase	Cancer
NSC139021 (ERGi-USU) is a RIOK2 inhibitor with anticancer activity. RIOK2 can highly selectively inhibit the growth of ERG-positive cancer cells with IC₅₀s of 30-400 nM against cell lines. RIOK2 also causes cell cycle arrest and apoptosis in glioblastoma via induction of Skp2 and Skp2-p27/p21-Cyclin E/CDK2-pRb signaling .

HY-15166

(E/Z)-Zotiraciclib Maximum Cited Publications 6 Publications Verification (E/Z)-TG02; (E/Z)-SB1317	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC₅₀s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .

HY-122620

Rafutrombopag (tautomerism) Hetrombopag (tautomerism); SHR-8735 (tautomerism)	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

HY-15166A

(E/Z)-Zotiraciclib hydrochloride Maximum Cited Publications 6 Publications Verification (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) is an orally active inhibitor of CDK2, JAK2 and FLT3 with IC₅₀s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .

HY-136726

CGP-82996 CINK4	CDK	Cancer
GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC₅₀s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .

HY-145589

Rafutrombopag Hetrombopag; SHR-8735	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology Cancer
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

HY-162318A

MYC degrader 1 TFA 1 Publications Verification	Molecular Glues c-Myc	Cancer
MYC degrader 1 TFA (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 TFA restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .

HY-201330

GDC-4198 RGT-419B	CDK	Cancer
GDC-4198 (RGT-419B) is an orally active CDK4/2 inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .

HY-RS11052

PRB2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PRB2 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PRB2 Human Pre-designed siRNA Set A PRB2 Human Pre-designed siRNA Set A

HY-RS11051

PRB1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PRB1 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PRB1 Human Pre-designed siRNA Set A PRB1 Human Pre-designed siRNA Set A

HY-RS11053

PRB3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PRB3 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PRB3 Human Pre-designed siRNA Set A PRB3 Human Pre-designed siRNA Set A

HY-RS11054

PRB4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PRB4 Human Pre-designed siRNA Set A contains three designed siRNAs for PRB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PRB4 Human Pre-designed siRNA Set A PRB4 Human Pre-designed siRNA Set A

HY-RS10397

Pgr Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pgr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pgr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pgr Mouse Pre-designed siRNA Set A Pgr Mouse Pre-designed siRNA Set A

HY-147220

Dexamethasone oxetanone Dex-Ox	Progesterone Receptor	Endocrinology
Dexamethasone oxetanone (Dex-Ox), a derivative of the glucocorticoid-selective steroid Dexamethasone (Dex), is an antiglucocorticoid. Dexamethasone oxetanone is an antiprogestin with significant agonist activity with progesterone receptor (PR) A and B isoforms .

HY-RS11713

RB1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RB1 Human Pre-designed siRNA Set A contains three designed siRNAs for RB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RB1 Human Pre-designed siRNA Set A RB1 Human Pre-designed siRNA Set A

HY-16290

Lonaprisan ZK 230211; BAY86 5044	Progesterone Receptor	Endocrinology
Lonaprisan (ZK 230211; BAY86 5044) is an antagonist for progesterone receptor, with IC₅₀ of 3.6 pM and 2.5 pM for PR-A and PR-B, respectively. Lonaprisan exhibits antiprogestagenic activity in rabbits, interrupts early pregnancy in rats, and exhibits antitumor efficacy against DMBA (HY-W011845)-induced mammary tumor. Lonaprisan reveals antiglucocorticoid and antiandrogenic effect .

HY-173007

ALK/PI3K/AKT-IN-1	Akt PI3K Anaplastic lymphoma kinase (ALK) CDK Apoptosis Mitochondrial Metabolism	Cancer
ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC₅₀ of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids .

HY-186132

*PROTAC CDK2-pRb* degrader-1**	PROTACs CDK	Cancer
PROTAC CDK2-pRb degrader-1 is an orally active PROTAC-class degrader of CDK2. PROTAC CDK2-pRb degrader-1 effectively inhibits the phosphorylation of retinoblastoma protein (Rb) at serine residues 807/811 by inducing ubiquitination and proteasomal degradation of CDK2. PROTAC CDK2-pRb degrader-1 exhibits significant activity against human cells (with EC₅₀ values of 12 nM and 125 nM, respectively). In xenograft models, PROTAC CDK2-pRb degrader-1 effectively inhibits tumor growth and induces tumor stasis, making it suitable for research related to CCNE1-amplified cancers (such as ovarian cancer, gastric cancer, and breast cancer) .

HY-185164

Anticancer agent 302	CDK	Cancer
Anticancer agent 302 (Example 1) is an anticancer agent. Anticancer agent 302 has a DC₅₀ value of 199 nM for Cyclin E1 and an IC₅₀ value of 133 nM for *pRB*. Anticancer agent 302 can be used for tumor research .

HY-RS16852

Rb1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rb1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rb1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rb1 Mouse Pre-designed siRNA Set A Rb1 Mouse Pre-designed siRNA Set A

HY-182447

Contragestazol DL111-IT	CDK Apoptosis	Endocrinology Cancer
Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G₀/G₁ phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals .

Cat. No.	Product Name

HY-L234

Nucleotide Metabolite Compound Library	82 compounds
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 82 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

Nucleotide Metabolite Compound Library

82 compounds

Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs.

MCE can provide 82 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.

HY-L201

Cell Proliferation Compound Library	3,367 compounds
Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others. MCE collects 3,367 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Cell Proliferation Compound Library

3,367 compounds

Cell proliferation, the increase in cell numbers resulting from cell division, is a complex and tightly regulated process. Cell proliferation is regulated by coordinated entry into the cell cycle, and changes in proliferation are closely linked to disease development. Evolutionary dynamics links tumor growth and progression with cell proliferation, cell death, and mutation rates. In addition, cell proliferation is central to degenerative diseases, the development of which is often accompanied by accelerated multiplication of cancer cells. Therefore, assays of cell proliferation levels are frequently used for laboratory research purposes and increasingly for clinical assessment of tumor aggressiveness and potentially to guide care. It has been shown that multiple key targets are collectively involved in regulating the process of cell proliferation, such as CDK, E2F, pRB, β-Catenin, and others.

MCE collects 3,367 compounds that target and regulate key targets of cell proliferation, which can be used in studies of cell proliferation mechanisms and drug discovery.

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703588

	RB1 Protein, Human (StrepⅡ) Retinoblastoma-associated protein; p105-Rb; p110-RB1; PRB; Rb; pp110; RB1; Homo sapiens; Human; Rb; Chromatin regulator; DNA-binding; Repressor	Human	E. coli
	RB1 Protein, Human (Strep) is the recombinant human-derived RB1, expressed by E. coli , with Strep labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (2) Rabbit (11)
Reactivity:	Human (13) Rat (5) Mouse (4) Hamster (2)
Application:	IHC-P (7) ICC/IF (4) IF-Tissue (1) IP (7) IHC-F (1) WB (13) FC (1) ELISA (1)
Isotype:	IgG (10) IgG/Kappa (1)
Conjugation:	Non-conjugated (13)
Clonality:	Monoclonal (9) Recombinant (6)
Modification:	Phosphorylated (5) Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85348

	Rb Antibody (YA5040) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, IP, FC	Human
	Rb Antibody (YA5040) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to Rb.

HY-P81301A

	Phospho-Rb (Ser780) Antibody (YA1030) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IP	Human, Mouse
	Phospho-Rb (Ser780) Antibody (YA1030) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Ser780).

HY-P81301B

	Phospho-Rb (Ser811) Antibody (YA1031) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB	Human, Hamster
	Phospho-Rb (Ser811) Antibody (YA1031) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Ser811).

HY-P81301

	Phospho-Rb (Thr356) Antibody (YA1029) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IHC-P, IP	Human
	Phospho-Rb (Thr356) Antibody (YA1029) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Thr356).

HY-P81301C

	Phospho-Rb (Ser608) Antibody (YA1032) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IHC-P	Human
	Phospho-Rb (Ser608) Antibody (YA1032) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Ser608).

HY-P81301D

	Phospho-Rb (Thr252) Antibody (YA1033) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IHC-P	Human
	Phospho-Rb (Thr252) Antibody (YA1033) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Thr252).

HY-P81301AA

	Phospho-Rb (Ser780) Antibody (YA1030)(PBS only) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IP	Human, Mouse
	Phospho-Rb (Ser780) Antibody (YA1030) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Ser780).

HY-P81301BA

	Phospho-Rb (Ser811) Antibody (YA1031)(PBS only) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB	Human, Hamster
	Phospho-Rb (Ser811) Antibody (YA1031) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Ser811).

HY-P81301CA

	Phospho-Rb (Ser608) Antibody (YA1032)(PBS only) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IHC-P	Human, Rat
	Phospho-Rb (Ser608) Antibody (YA1032) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Ser608).

HY-P81301DA

	Phospho-Rb (Thr252) Antibody (YA1033)(PBS only) RB1; Retinoblastoma-associated protein; p105-Rb; PRB; Rb; pp110	WB, IHC-P	Human, Rat
	Phospho-Rb (Thr252) Antibody (YA1033) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Rb (Thr252).

HY-P86428

	E2F-1 Antibody (YA6120) E2F1; RBBP3; Transcription factor E2F1; E2F-1; PBR3; Retinoblastoma-associated protein 1; RBAP-1; Retinoblastoma-binding protein 3; RBBP-3; PRB-binding protein E2F-1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	E2F-1 Antibody (YA6120) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to E2F-1.

HY-P85613

	E2F-1 Antibody (YA5305) Dmel\CG6376; Dmel_CG6376; drosE2F1; E; Sev-CycE; 3A; E; var; 3-93E; E2-promoter binding facto; E2F 1; E2F transcription factor 1; E2F-1; E2f-PA; E2f-PB; E2f-PC; E2F1; E2f1 E2F transcription factor 1; E2F1_HUMAN; Evar; 3; 164; KIAA4009; l; 3; 07172; l; 3; j3B1; l; 3; j3C2; l; 3; rM729; mKIAA4009; OTTHUMP00000030661; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma-associated protein 1; Retinoblastoma-binding protein 3; Transcription factor E2F1.	WB, ICC/IF, IP	Human, Rat
	E2F-1 Antibody (YA5305) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to E2F-1.

HY-P85616

	EIF2S1 Antibody (YA5308) Dmel\CG6376; Dmel_CG6376; drosE2F1; E; Sev-CycE; 3A; E; var; 3-93E; E2-promoter binding facto; E2F 1; E2F transcription factor 1; E2F-1; E2f-PA; E2f-PB; E2f-PC; E2F1; E2f1 E2F transcription factor 1; E2F1_HUMAN; Evar; 3; 164; KIAA4009; l; 3; 07172; l; 3; j3B1; l; 3; j3C2; l; 3; rM729; mKIAA4009; OTTHUMP00000030661; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma-associated protein 1; Retinoblastoma-binding protein 3; Transcription factor E2F1.	WB, ICC/IF, IP	Human, Mouse, Rat
	EIF2S1 Antibody (YA5308) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to EIF2S1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: